Trimebutine Maleate can improve symptoms such as loss of appetite, nausea, vomiting, belching, bloating, abdominal belching, abdominal pain, and diarrhea constipation caused by gastrointestinal motility disorders. It also has a certain effect on intestinal irritable syndrome.
1) Gastric regulation. The addition of 10-5 g/ml of the drug to the vestibular ring muscle specimen of the isolated guinea pig can reduce the amplitude of the autonomous movement of the circular muscle. In addition: it is also possible to increase the frequency and amplitude of the irregular weak motion of the same specimen at 28 ° C, so that it tends to regular rhythmic contraction. When intravenously injecting 3 mg/kg of the drug into an anesthetized dog that cuts the chest vagus nerve, the irregular movement of the stomach tends to be regularized.
For patients with digestive diseases, gastric pyloric movement, after intravenous injection of 1mg/kg, was found to inhibit the movement of motor function muscles. At the same time, it was also found to enhance the movement of lower motor muscles.
2) Induced by the digestive system propulsive movement. In the human jejunum, 4 to 6 mg / kg. Find. It can induce physiological digestive tract propulsion in the adult digestive system.
3) Improvement of gastric emptying function. Patients with chronic gastritis who have unreasonable unreasonable upper abdominal digestive tract after oral administration can increase gastric emptying function after oral administration of 200 mg. At the same time, it can also inhibit hyperactivity of gastric emptying function.
4) Intestinal motor regulation.
5) Experiments on isolated guinea pig colon specimens. When using 10-5 g/ml, the muscle tension is low (at low load), the tension is increased, and the muscle tension is increased (at high load), which reduces the tension and reduces the amplitude. · Hyperintestinal hyperactivity caused by the psychological exertion load of irritable bowel syndrome. Taking 300 mg can be inhibited. • For patients with exercise-induced hyperactivity, intravenous administration of 50 mg inhibits ileum, ascending colon, and sigmoid colon movement to pre-load levels.
6) Regulation of the lower esophageal sphincter pressure (LESP). The lower esophageal sphincter pressure test of anesthetized dogs showed that 0.6 mg/kg intravenous administration can reduce the increase of internal pressure caused by tetrapeptide-induced gastrin load, and also reduce the internal pressure caused by intestinal secretin.
7) Direct effect on the smooth muscle of the digestive tract. The experiment on the vestibular ring muscle specimens of isolated guinea pig stomach found that even in the presence of atropine, phentolamine, propranolol and tetrodotoxin, the drug has a direct effect on the smooth muscle of the digestive tract. • Experiments on isolated guinea pig ileum have found that this agent can non-competitively inhibit the contraction caused by acetylcholine. It has also been found that after removal of the anesthetized canine chest vagus nerve, there is still a direct effect on digestive tract movement.
In dogs, it has been found that although the inhibitory effect on apomorphine-induced vomiting is weak, the time required for vomiting can be significantly prolonged after intravenous injection of 3 mg/kg or oral 60 mg/kg due to copper sulfate-induced vomiting.